Formulation Development
Gelteq Announces 400,000 Units Enter Production in November 2024
Gelteq Limited recently announced that in November, 400,000 units of its gel solution are entering into production. These units will fulfill orders made for clients…
Adragos Pharma Acquires Leading Swiss Sterile Fill-Finish Expert
Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. This acquisition significantly enhances Adragos’ sterile manufacturing capabilities and marks a pivotal step…
Kanglin Biotechnology Announces $20-Million Financing to Advance the Development of Gene Therapies
Kanglin Biotechnology (Hangzhou) Co., Ltd, an innovative biotech company developing the next generation of gene therapies, recently announced the successful completion of a Series A…
IMUNON Announces Results From its End-of-Phase 2 Meeting With the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
IMUNON, Inc. recently announced the outcome of its recent End-of-Phase 2 in-person meeting with the US FDA, supporting the advancement of its investigational interleukin-12 (IL-12)…
Tenaya Therapeutics Doses First Patient in Phase 1b Clinical Trial for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics, Inc. recently announced the first patient has been dosed with TN-401 gene therapy in the RIDGE-1 Phase 1b clinical trial at the University…
CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form
In this CPHI Award-winning case study, learn how Adare scientists took the alternative sprinkle version out of the lab and into the hands of patients.
ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products
Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs.
OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AML
OncoVerity recently announced the closing of a Series A extension financing led by existing investors, argenx and RefinedScience. With this funding, OncoVerity aims to advance…
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
Lipella Pharmaceuticals Inc. recently announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral…
UMDF & Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease
The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical stage biopharmaceutical company discovering and developing therapies…
BriaCell Announces First Patient Dosed With Bria-OTS in Metastatic Breast Cancer Study
BriaCell Therapeutics Corp. recently announced the first patient was dosed in its Phase 1/2 study (ClinicalTrials.gov identifier: NCT06471673) to evaluate the safety and efficacy of…
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV & Malaria Using C1 Platform Technology
Dyadic International, Inc. recently announced it has been awarded a $3 million grant from the Gates Foundation for the cell line development of monoclonal antibodies…
GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines & Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently announced the presentation of positive preclinical data demonstrating its lead program GRI-0621 reduces important inflammatory and fibrotic drivers in Idiopathic Pulmonary…
Eradivir’s Therapeutic Proven to Reduce Advanced-Stage Influenza Viral Loads Faster, More Thoroughly in Preclinical Studies Than Current Therapies
Eradivir has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available…
Abzena Expands Analytical Capabilities to Include GMP Cell-Based Potency Testing Across US & UK Sites
Abzena recently announced the expansion of their early and late phase analytical capabilities to now include GMP cell-based potency assays at their Cambridge, UK and San…
Lonza Announces First GMP Batch Completion at Next-Generation Mammalian Manufacturing Facility in Portsmouth (US)
Lonza, a global development and manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced the completion of the first GMP product batch supported…
Verge Genomics Announces Milestones in Collaboration With Lilly to Discover & Develop Novel Treatments for ALS
Verge Genomics recently announced Eli Lilly & Company has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis…
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
Voyager Therapeutics, Inc. recently announced it has selected a lead development candidate, VY1706, for its tau silencing gene therapy program in Alzheimer’s disease. The company…
ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for Aicardi Goutières Syndrome Treatment
ImmuneSensor Therapeutics recently announced the US FDA has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for the company’s lead anti-inflammatory…
Genezen Appoints New Chief Operations Officer
Genezen recently announced the appointment of Mike Wourms as Chief Operations Officer. This appointment bolsters Genezen’s strategic growth plan and comes at a time of…
